Skip to main content

Table 6 Amendments to the study protocol post pilot phase

From: Barrett’s oESophagus trial 3 (BEST3): study protocol for a randomised controlled trial comparing the Cytosponge-TFF3 test with usual care to facilitate the diagnosis of oesophageal pre-cancer in primary care patients with chronic acid reflux

Pilot study findings

Amendments to study protocol

Female to male ratio slightly higher than 50:50 overall

If the proportion of females to males consistently exceeds 55:45 within the overall cohort, the study team may institute a 50:50 split for females: males in line with known BE prevalence, at the discretion of the Trial Statistician.

Cytosponge™ appointment uptake < 50%

Patients will receive a total of one reminder in the form of a letter, phone call or text message.

Time required for practice and patient recruitment might take longer for each practice than anticipated

Practices recruited in the latter stages of the trial may adopt a 6 month follow-up period to allow timely completion of study activities with a simulation tool used to ensure parity across the datasets.